JDRF T1D Fund
The T1D Fund is a Boston-based venture philanthropy fund (founded 2016) that makes equity investments in early-stage biotech companies developing disease-modifying therapies and cures for Type 1 Diabetes, co-investing with VCs and biopharma as a wholly owned subsidiary of Breakthrough T1D.
- Company typePrivate
- Founded2016
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What JDRF T1D Fund does
The T1D Fund (legally "The T1D Fund: A Breakthrough T1D Venture, LLC") is a Boston-based venture impact fund founded in 2016 as the first scaled venture vehicle exclusively devoted to accelerating treatments, prevention, and cures for Type 1 Diabetes. It operates as a wholly owned not-for-profit subsidiary of Breakthrough T1D (formerly JDRF), a 501(c)(3) organization, and is governed by an independent Investment Committee. The fund makes equity investments in early-stage biotech companies pursuing disease-modifying therapies and curative approaches, co-investing alongside venture capital firms and biopharmaceutical companies across autoimmune and regeneration, cell replacement, and metabolic control modalities. Notable portfolio companies include Sana Biotechnology, Century Therapeutics, Aspect Biosystems, Sonoma Biotherapeutics, DiogenX, Zucara Therapeutics, and Zag Bio, among 25+ companies invested since inception.
The fund's business model is impact-driven and evergreen: capital is sourced through charitable contributions from donors, family foundations, and Breakthrough T1D itself (including a recently announced $150+ million capital raise campaign), and 100% of investment returns are reinvested into new T1D investments rather than distributed. With $250M+ in assets under management, the fund deploys catalytic capital to de-risk programs and create a flywheel effect that attracts additional investors to the T1D space, while providing portfolio companies with access to Breakthrough T1D's research, clinical, regulatory, and medical affairs networks. The fund is based at 50 Milk Street, 16th Floor, Boston, MA 02109, and is supported by an 11-50 person team led by CEO Elizabeth Mily alongside Managing Directors Sylvia Tobé and Lucio Iannone, with recent senior additions including Head of Strategy & Industry Engagement Daniel McNamara and strategic consultant Teresa Foy, Ph.D.
JDRF T1D Fund firmographics
Firmographics- Name
- JDRF T1D Fund
- Legal name
- The T1D Fund: A Breakthrough T1D Venture, LLC
- Website
- https://t1dfund.org
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- The T1D Fund is a Boston-based venture philanthropy fund (founded 2016) that makes equity investments in early-stage biotech companies developing disease-modifying therapies and cures for Type 1 Diabetes, co-investing with VCs and biopharma as a wholly owned subsidiary of Breakthrough T1D.
- Ownership category
- akta.pro rank
JDRF T1D Fund industry classification
Industry- Product category
- Venture Philanthropy / Impact Investment Fund
- NAICS
- Open-End Investment Funds (525910)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- SDG / Thematic Sustainable Investment Funds (FSANAJAN)
- akta.pro secondary industry
- Impact Investing & Social Finance (Funds, CDFIs, Microfinance) (BPAGALAA)
Keywords
Where JDRF T1D Fund is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
JDRF T1D Fund business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales
Revenue model
- Impact Investment Returns: As an evergreen impact investment fund, the T1D Fund makes equity investments in biotech companies pursuing T1D treatments and cures. All returns from investments are reinvested into new investments, creating a continuous cycle of progress that fuels foundational research and accelerates program development.
- Charitable Contributions: Funded through charitable contributions from donors and from Breakthrough T1D itself. As a wholly owned subsidiary of Breakthrough T1D, a 501(c)(3) organization, all donor contributions raised for the Fund are recorded as charitable donations where donors receive tax benefits.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
JDRF T1D Fund product offering
Product offeringCore offering
The JDRF T1D Fund is a venture impact fund that makes equity investments in early- and clinical-stage biotech companies developing treatments and cures for Type 1 Diabetes. The fund, a wholly owned subsidiary of Breakthrough T1D (formerly JDRF), manages $250M+ in committed capital across 20+ active portfolio companies and reinvests 100% of investment returns back into the T1D mission. It also operates a co-investment platform that enables accredited investors and biopharma partners to participate alongside the fund in T1D financings.
Product overview
The T1D Fund operates as a single venture impact fund platform focused on catalyzing treatments, prevention, and cures for type 1 diabetes. The fund makes equity investments in early-stage biotech companies through its co-investment platform, supporting companies across immunotherapy, beta cell therapy, metabolic control, and improving lives approaches. With $250M+ in assets under management and 20+ active portfolio companies (including Aera Therapeutics, Adaxion Therapeutics, AltruBio, Aspect Biosystems, Bigfoot Biomedical, Biolinq, Century Therapeutics, COUR Pharmaceuticals, DiogenX, GentiBio, Immunocore, Inversago Pharma, Jaguar Gene Therapy, Kriya Therapeutics, Mozart Therapeutics, Sana Biotechnology, Semma Therapeutics, Sonoma Biotherapeutics, ZagBio, Zucara Therapeutics, and others), the fund provides investment capital alongside strategic support, leveraging the network and expertise of Breakthrough T1D. All returns are reinvested into the fund to fuel continued progress in T1D therapeutic development.
Differentiator
Problem solved
Functional benefit
Products and services
- JDRF T1D Fund Venture Impact Fund Equity investment fund making venture-stage investments into early- and clinical-stage biotech companies developing disease-modifying, curative, prevention, beta cell replacement, and diagnostic therapies for Type 1 Diabetes. Targeted at founders and management teams of T1D-focused biotech companies.
- T1D Co-Investment Platform Syndication platform that allows accredited investors, family offices, VC firms, and biopharma strategic partners to participate alongside the JDRF T1D Fund in portfolio company financings through a donor-advised fund (ImpactAssets) structure with preferred-return economics.
Companies that use JDRF T1D Fund
Customer profileSegments1 record
Ideal customer profiles2 records
JDRF T1D Fund technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
JDRF T1D Fund partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Breakthrough T1DcoreThe T1D Fund is a wholly owned subsidiary of Breakthrough T1D (formerly JDRF), the leading global organization focused on finding a cure for T1D. Breakthrough T1D provides the fund with access to extensive research, clinical, regulatory, and medical affairs network to support portfolio companies.
Scale indicators6 records
Recent moves7 records
Expansion highlights5 records
JDRF T1D Fund competitors and assessment
Company assessmentDirect peers
- Multiple Myeloma Research Foundation: Patient-organization-led venture philanthropy that has co-funded and co-invested in myeloma biotech programs alongside venture capital. Same disease-focused donor-funded impact-investment model.
- Cancer Research Institute: Patient-org-adjacent funder that has grown a venture-style impact program (e.g., the Cancer Research Institute Technology Impact Fund) backing biotech companies in immuno-oncology. Same template as T1D Fund applied to a different disease area.
- LifeArc: UK-based medical research charity that has built a venture arm (LifeArc Ventures) making equity investments in early-stage biotech. Notable structural peer because it sits inside a charitable parent and reinvests returns into translational science.
- Alzheimer's Drug Discovery Foundation: Direct disease-focused venture philanthropy fund that makes equity and convert investments in biotech pursuing disease-modifying Alzheimer's therapies. Identical structure: donor-funded impact fund with an experienced investment team and scientific network.
- Cystic Fibrosis Foundation: Operates a venture philanthropy program (CFF Therapeutics Lab) that has made equity-like investments in CF-focused biotech for decades. Direct comparable as a disease-focused impact-investment vehicle incubated by a patient organization.
- Michael J. Fox Foundation for Parkinson's Research: Patient-organization-led venture philanthropy fund accelerating disease-modifying Parkinson's therapeutics. Highly comparable model in mission alignment, donor-funded investing, and emphasis on de-risking translational academic science.
Emerging players
- PureTech Health: Publicly listed R&D and venture entity that founds and incubates biotech companies targeting immunology, metabolic, and CNS indications — model-comparable to T1D Fund's catalytic company-creation approach, though PureTech is profit-driven rather than donor-funded.
- Harrington Discovery Institute: Academic- and foundation-backed drug-discovery accelerator that funds and provides non-dilutive capital plus venture-style support to physician-scientist spinouts. Overlapping model (Harrington scholars + investment vehicle) but more academic and less equity-driven than T1D Fund.
Broad incumbents
- The Leona M. and Harry B. Helmsley Charitable Trust: Major healthcare-focused private foundation and a foundational partner of T1D Fund itself. Comparable as a large-scale philanthropic funder backing disease-specific translational research and venture philanthropy, though operating with grants more than equity.
- RA Capital Management: Boston-based biotech crossover and venture investor whose TechAtlas division focuses on company creation and disease-area theses. Comparable as a Boston-based specialist biotech investor that co-invests with biopharma alongside T1D Fund.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
JDRF T1D Fund social profiles
Digital presenceJDRF T1D Fund financial estimates
Financial estimateRevenue estimate
Valuation estimate
JDRF T1D Fund leadership team
Management profileNumber of profiles
Profiles11 records
JDRF T1D Fund funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
JDRF T1D Fund M&A and investment
M&A and investmentM&A
Investments54 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about JDRF T1D Fund
What does JDRF T1D Fund do?
The JDRF T1D Fund is a venture impact fund that makes equity investments in early- and clinical-stage biotech companies developing treatments and cures for Type 1 Diabetes. The fund, a wholly owned subsidiary of Breakthrough T1D (formerly JDRF), manages $250M+ in committed capital across 20+ active portfolio companies and reinvests 100% of investment returns back into the T1D mission. It also operates a co-investment platform that enables accredited investors and biopharma partners to participate alongside the fund in T1D financings.
Is JDRF T1D Fund a public or private company?
JDRF T1D Fund is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was JDRF T1D Fund founded?
JDRF T1D Fund was founded in 2016. It employs 11 to 50 people.
Where is JDRF T1D Fund based?
JDRF T1D Fund is headquartered in Boston, United States, in the North America region.
How does JDRF T1D Fund make money?
Two revenue lines are on record. Impact Investment Returns are the primary driver. The others are charitable Contributions.
Who are JDRF T1D Fund's main competitors?
Direct peers on record are Multiple Myeloma Research Foundation, Cancer Research Institute, LifeArc, Alzheimer's Drug Discovery Foundation, Cystic Fibrosis Foundation and Michael J. Fox Foundation for Parkinson's Research. Emerging players are PureTech Health and Harrington Discovery Institute. Broad incumbents are The Leona M. and Harry B. Helmsley Charitable Trust and RA Capital Management.
Does JDRF T1D Fund have an API?
No public API is recorded for JDRF T1D Fund.
What industry is JDRF T1D Fund in?
JDRF T1D Fund's product category is Venture Philanthropy / Impact Investment Fund. Its primary akta.pro industry code is FSANAJAN, SDG / Thematic Sustainable Investment Funds, with a secondary code of BPAGALAA, Impact Investing & Social Finance (Funds, CDFIs, Microfinance). Its NAICS code is 525910 and its SIC code is 6282.